Sutterella

Role in Gut Ecosystem#

Adheres to intestinal epithelial cells and resides within the mucosal layer, positioning it in close contact with the host immune system.

Produces IgA proteases that degrade secretory immunoglobulin A, the primary antibody defending mucosal surfaces. This IgA-degrading activity may impair mucosal immunity and facilitate pathogen invasion or immune dysregulation.

Relatively bile-resistant, allowing colonization of the small intestine and colon. Does not produce significant Short-Chain Fatty Acids (SCFAs), distinguishing it from beneficial anaerobes in similar ecological niches.

Autism Spectrum Disorder#

Consistently enriched in ASD across multiple studies, making it one of the more reproducible ASD-associated taxa.^{[1]Bezawada 2020 — Autism Spectrum Disorder and the Gut Microbiota in Children: A Systematic ReviewNavya Bezawada, Tze Hui Phang, Georgina L. Hold et al. · 2020Open reference 1 ↓}

IgA degradation may contribute to the increased gut permeability ("leaky gut") reported in ASD children, potentially allowing microbial metabolites and bacterial products to cross the gut barrier and affect the CNS via the Gut-Brain Axis.

Multiple Sclerosis#

Increased in MS patients on immunomodulatory therapy (treatment effect rather than disease effect), suggesting that immune suppression may create a niche for Sutterella expansion.^{[2]Alterations of the human gut microbiome in multiple sclerosisSushrut Jangi, Roopali Gandhi, Laura M. Cox et al. · 2016Open reference 2 ↓}

May benefit from reduced IgA pressure under immunomodulatory treatment, consistent with its IgA-degrading phenotype.

Inflammatory Bowel Disease#

Contradictory findings: enriched in some IBD cohorts (particularly in mucosal biopsies) but depleted in others (stool-based studies). This inconsistency may reflect differences between mucosal and luminal sampling, disease phase, or IBD subtype.^{[3]Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?V. Martinelli, M. Albanese, M. Altieri et al. · 2022Open reference 3 ↓}

Detected in intestinal biopsies of patients with Crohn's Disease and ulcerative colitis, suggesting mucosal colonization preference.^{[4]Feeding the gut microbiome: impact on multiple sclerosisMatteo Bronzini, Alessandro Maglione, Rachele Rosso et al. · 2023Open reference 4 ↓}

Mechanistic Considerations#

The IgA-degrading capacity of Sutterella provides a clear mechanistic link to mucosal immune impairment. In the healthy gut, secretory IgA coats commensal bacteria and neutralizes pathogens; its degradation could destabilize the entire mucosal immune equilibrium.

The increase under immunomodulatory therapy in MS suggests Sutterella is normally kept in check by robust mucosal immunity, and its expansion may be a consequence rather than cause of immune dysregulation.

As a Proteobacteria member, its enrichment may reflect the broader "Proteobacteria bloom" seen in inflammatory conditions.